Earnings Call Insights: Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

Partnerships to help create more todays and better tomorrows for bladder cancer patients and families BETHESDA, Md., April 15, 2025 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN ...

Partnerships to help create more todays and better tomorrows for bladder cancer patients and families BETHESDA, Md., April 15, 2025 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN ...